Antifungals
Oral posaconazole has clinical activity against CNS fungal infections
Published in AIDS Weekly, December 5th, 2005
According to recent research published in the Journal of Antimicrobial Chemotherapy, "A multinational, multicenter, open-label clinical trial was conducted to evaluate the safety and efficacy of posaconazole, an extended-spectrum triazole antifungal agent, in subjects with invasive fungal infections who had refractory disease or who were intolerant of standard antifungal therapy. In this subanalysis, we report on those subjects in this trial who had a fungal infection that involved the CNS."
"Subjects received posaconazole oral suspension 800...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-12-05)
More Articles from AIDS Weekly
- Behavioral Medicine
POZ parties are an emerging risk for HIV-infected men who have unprotected sex with men - HIV/AIDS Diagnostics
Rapid HIV tests more cost effective than ELISAs in low-risk populations - HIV/AIDS Diagnostics
Screening assay detects CD8+ cell noncytotoxic anti-HIV response - HIV/AIDS Transmission
CD8 cell presence in semen does not correlate with levels of HIV-1 RNA shedding - HIV/AIDS Transmission
Chorioamnionitis is associated with placental transmission of HIV-1 subtype E - Antimicrobials
Xanthohumol is a broad-spectrum anti-infective agent - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
